Clinical Trial Finder

Inclusion Criteria:

1. Neuroblastoma must be documented at the point of diagnosis, which is defined as one of the following: histopathology of a biopsy of a solid tumour; bone marrow aspirate or biopsy suggestive of neuroblastoma with elevated blood or urine catecholamine metabolite levels. 2. The participant is at least 6years old at time of enrollment. 3. At least one measurable lesion at baseline according to RECIST version 1.1. 4. Have adequate organ function as assessed by the laboratory required by protocol, which should be confirmed within 2 weeks prior to the first dose of study drugs. 5. Previous treatment must be completed for more than 4 weeks prior to the enrollment of this study, and subjects have recovered to <= grade 1 toxicity. 6. Eastern Cooperative Oncology Group (ECOG) performance status score≤2 and Estimated life expectancy of more than 3 months. 7. Patient(and/ or their parent/ legal guardian) is willing to participate and able to provide signed informed consent.

Exclusion Criteria:

1. Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF. 2. Existing major organ dysfunction > Grade 2, with the exception of hearing loss, hematological status, kidney and liver function. 3. Active life-threatening infection. 4. History of allergy or intolerance to study drug components. 5. The participant is CYP2D6 ultra-rapid metabolizer. 6. The participant is known to be allergy to Eliglustat. 7. The participant use drugs that will strongly inhibit CYP2D6 or CYP3A activity.

Neuroblastoma is the most common extracranial solid tumour in infants and children. It is also known as an immunocold tumour due to the poor infiltration of immune cells in the tumour microenvironment. Tumour-associated macrophages and myeloid-derived suppressor cells account for a significant proportion of neuroblastoma cases and predominantly exert a pro-tumourigenic effect due to the tumour-suppressive microenvironment. Anti-phagocytic signals expressed by tumour cells, such as CD47, inhibit the direct cytophagy of macrophages. Patients in the high-risk group are less immunogenic and therefore less responsive to immune-checkpoint inhibitor (ICI) monotherapy than those in the low- and intermediate-risk groups. A combination of approaches may therefore be required for the immunotherapy of neuroblastoma. Aberrant expression of glycosphingolipid (GSL) synthase is a fundamental feature of most tumours and tumour microenvironments. Neurological tumours, including neuroblastoma, have been observed to exhibit elevated levels of acidic glycosphingolipids on their surfaces. A number of studies have indicated that there is an increase in the expression of GSL synthase in tumours that are resistant to chemotherapy. Eliglustat, an oral GlcCer synthase inhibitor, has been approved for the treatment of Gaucher disease type 1. Researchers have demonstrated the excellent safety and efficacy of Eliglustat in combination with immune checkpoint inhibitors for treating advanced/metastatic solid tumours and relapsed/refractory haematological malignancies. For these reasons, an exploratory clinical study was designed to observe the efficacy and feasibility of GSL synthase inhibitors in combination with GM-CSF in the treatment of patients with advanced/metastatic neuroblastoma. The objective of this study was to provide a high level of evidence-based rationale for the combination treatment regimen in these patients. The investigators will administer a combination of Eliglustat and GM-CSF to six patients diagnosed with advanced or metastatic NB. The primary objective of this study is to assess the efficacy and feasibility of Eliglustat in combination with GM-CSF in the treatment of neuroblastoma. The secondary objectives are to assess immunological or clinically predictive biomarkers of efficacy and toxicity, alterations in the tumour microenvironment, and changes in the dynamics of immune cells in the peripheral blood.

Arms

Experimental: GM-CSF + Eliglustat

Eliglustat 42mg will be administered twice daily in patients in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be administered twice daily every other week to 96 weeks. Prior to the initiation of Eliglustat, GM-CSF was administered for a period of five days at a dose of 250 µg/m2/day. Subsequent to this, GM-CSF is administered at a dosage of 500 µg/m2/day on Days 1-5.

Interventions

Drug: - Eliglustat

Drug: GM-CSF + Eliglustat Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and GSL Synthetase Inhibitor